Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.

Regency Centers Corporation

An announcement from Eregli Demir Ve Celik Fabrikalari T.A.S. ( ($TR:EREGL) ) is now available. Ereğli Demir ve Çelik Fabrikaları T.A.Ş. (Eregli) o...

Eregli Steel Shares Converted to Tradable Stock on Turkish Exchange

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Regeneron, with a price target of $737.00. According to Tip...

RBC Capital Sticks to Their Hold Rating for Regeneron (REGN)

Creactives Group S.p.A. ( ($IT:CREG) ) has issued an update. Creactives Group S.p.A. reported a strong increase in activity for the financial year ...

Creactives boosts recurring revenue and profitability as international and partner business expand

Empa Elektronik Sanayi ve Ticaret A.S. ( ($TR:EMPAE) ) has shared an announcement. Turkey’s Capital Markets Board has updated its list of non-publi...

CMB Reclassifies Restricted Share Classes, Empa Elektronik Included in Non-Tradable List

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The extension study “A Double-blinded Exten...

Itepekimab COPD Extension Trial Completion: What It Means for Regeneron and Sanofi

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Regis Healthcare Ltd. on September 15 and set a price target of A$5.00. Wong-Pan cov...

RBC Capital Remains a Hold on Regis Healthcare Ltd. (REG)

UBS analyst maintained a Buy rating on RemeGen Co. Ltd. Class H on September 15 and set a price target of HK$132.50. The company’s shares closed ye...

UBS Sticks to Its Buy Rating for RemeGen Co. Ltd. Class H (9995)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals, Inc. is advancing a late-stage he...

Regeneron’s ROXI-EVEREST Trial Puts a New Stroke Drug in the Spotlight

Regis Healthcare Ltd. ( ($AU:REG) ) has provided an announcement. Regis Healthcare has disclosed changes in the indirect shareholdings of director ...

Regis Healthcare Director Increases Indirect Shareholding

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. Regeneron (REGN) and Sanofi (SNYNF) have co...

Regeneron and Sanofi Complete Key Dupilumab Itch Study, Expanding Dermatology Upside

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The STYLE 1 study is a Phase 3 trial run by...

Dupixent’s Next Move: STYLE 1 Itch Study Wraps Up for Regeneron and Sanofi

Regency Centers ( ($REG) ) has provided an announcement. Regency Centers Corporation, a U.S. REIT specializing in grocery-anchored shopping centers...

Regency Centers Updates Investor Presentation on Strategy

Regency Centers ( ($REG) ) just unveiled an update. On September 11, 2026, Regency Centers Corporation released an updated investor presentation, m...

Regency Centers Updates Investor Presentation for Shareholders

There’s a lot to be optimistic about in the Real Estate sector as 2 analysts just weighed in on Federal Realty (FRT) and Regency Centers (REG) with...

Analysts Offer Insights on Real Estate Companies: Federal Realty (FRT) and Regency Centers (REG)

Regis Healthcare Ltd. ( ($AU:REG) ) just unveiled an update. Regis Healthcare Ltd. has applied for quotation on the ASX of 68,543 new ordinary full...

Regis Healthcare Seeks ASX Quotation for New Employee Scheme Shares

The latest update is out from Regis Healthcare Ltd. ( ($AU:REG) ). Regis Healthcare Ltd has disclosed a change in director Graham Kennedy Hodges’ i...

Regis Director Hodges Increases Indirect Shareholding via On-Market Purchase

The latest announcement is out from Regis Healthcare Ltd. ( ($AU:REG) ). Regis Healthcare Ltd has reported a change in director Sally Margaret Free...

Regis Healthcare Director Sally Freeman Increases Shareholding

RBC Capital analyst Craig Wong-Pan downgraded Regis Healthcare Ltd. to a Hold yesterday and set a price target of A$5.00. Wong-Pan covers the Healt...

RBC Capital downgrades Regis Healthcare Ltd. (REG) to a Hold

In a report released today, from Macquarie maintained a Buy rating on Regis Healthcare Ltd., with a price target of A$5.90. In addition to Macquari...

Regis Healthcare Ltd. (REG) Receives a Buy from Macquarie

Regis Healthcare Ltd. received a Hold rating and a A$6.00 price target from Ord Minnett analyst Tom Godfrey today. Godfrey covers the Healthcare se...

Ord Minnett downgrades Regis Healthcare Ltd. (REG) to a Hold

In a report released today, David Low from UBS maintained a Hold rating on Regis Healthcare Ltd., with a price target of A$5.95. Low covers the Hea...

UBS Sticks to Its Hold Rating for Regis Healthcare Ltd. (REG)

The latest update is out from RemeGen Co. Ltd. Class H ( ($HK:9995) ). RemeGen Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong...

RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products

Regis Healthcare Ltd. ( ($AU:REG) ) has issued an announcement. Regis Healthcare Ltd has disclosed a change in the shareholding of director Carmel ...

Regis Healthcare Director Increases Shareholding via On‑Market Trade

Eregli Demir Ve Celik Fabrikalari T.A.S. ( ($TR:EREGL) ) has issued an announcement. Ereğli Demir ve Çelik Fabrikaları T.A.Ş. has notified the Cent...

Ereğli Iron and Steel Notifies Market of Share Conversion to Tradable Stock

Morgan Stanley analyst maintained a Hold rating on RemeGen Co. Ltd. Class H on August 25 and set a price target of HK$98.00. The company’s shares c...

Morgan Stanley Sticks to Their Hold Rating for RemeGen Co. Ltd. Class H (9995)

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study titled “A Randomized, Double-blin...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REG	$72.92	+0.26%	1.47M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REG	$72.92	+0.3%	1.47M
3
4
5
6

REG

Get Regency Centers Corporation Data in Excel

Get Regency Centers Corporation Data in Excel